Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials

AIMS: Several randomized trials and a previous meta-analysis have shown significant benefits from Gp IIb-IIIa inhibitors, especially abciximab. Recent randomized trials (BRAVE-3 and HORIZON trials) have shown no benefits from adjunctive Gp IIb-IIIa inhibitors on the top of clopidogrel administration...

Descripción completa

Detalles Bibliográficos
Autores principales: De Luca, Giuseppe, Navarese, Eliano, Marino, Paolo
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2009
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2777025/
https://www.ncbi.nlm.nih.gov/pubmed/19875386
http://dx.doi.org/10.1093/eurheartj/ehp118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2777025/
https://www.ncbi.nlm.nih.gov/pubmed/19875386
http://dx.doi.org/10.1093/eurheartj/ehp118

Ejemplares similares